Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2019 / N 1

Гиперурикемия и сердечно-сосудистые заболевания: cовременные аспекты терапии
В.В. Цурко, М.А. Громова, Ю.Б. Червякова, А.А. Копелев

Список литературы

1. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. International Journal of Cardiology 2016 Jun;213:8-14.
2. Gaffo AL, Lawrence EN, Saag KG. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Research & Therapy 2009;11(4):240-9.
3. Hari Kumar KVS, Marwaha V. Chronic tophaceous gout. International Journal of Medical and Health Sciences 2012;1(1):31-2.
4. Ревматология. Национальное руководство. Под ред. Насонова Е.Л., Насоновой В.А. М.: Гэотар-Медиа; 2008. 720 с.
5. Компания «Эгис» собрала статистику о распространенности гиперурикемии среди российских пациентов. Доступно по: http://www.egis.ru/news/232-kompaniya-egis-sobrala-statistiku-o-rasprostranennosti-giperurikemii-v-sochetanii-s-arterialnoj-gipertenziej-i-soputstvuyushchimi-zabolevaniyami-sredi-rossijskikh-patsientov Ссылка активна на 24.04.2019.
6. Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, Woolf A, March L. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases 2014 Aug;73(8):1470-6.
7. Roddy E, Choi HK. Epidemiology of gout. Rheumatic Diseases Clinic of North America 2014 May;40(2):155-75.
8. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, Burnier M. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004 Mar;4:9.
9. Qiu L, Cheng XQ, Wu J, Liu JT, Xu T, Ding HT, Liu YH, Ge ZM, Wang YJ, Han HJ, Liu J, Zhu GJ. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health 2013 Jul;13:664.
10. Liu S C, Xia L, Zhang J, Lu XH, Hu DK, Zhang HT, Li HJ. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS One 2015 Jul;10(7):e0134088.
11. Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Annals of the Rheumatic Diseases 2015 Apr;74(4):642-7.
12. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007 Aug;116(8):894-900.
13. Norvik JV, Storhaug HM, Ytrehus K, Jenssen TG, Zykova SN, Eriksen BO, Solbu MD. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: the Tromsø study. BMC Cardiovascular Disorders 2016;16:85-98.
14. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, Weiss ST, Litonjua AA. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006 Dec;48(6):1031-6.
15. Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. Journal of Hypertension 2007 Aug;25(8):1583-9.
16. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the third National Health and Nutrition Examination Survey. Arthritis and Rheumatism 2007 Feb;57(1):109-15.
17. Puig JG, Martínez MA. Hyperurecemia, gout and the metabolic syndrome. Current Opinion in Rheumatology 2008 Mar;20(2):187-91.
18. Borona E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998 Oct;47(10):1643-9.
19. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 Dec;288(21):2709-16.
20. Dessein P, Shipton E, Stanwix A, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Annals of the Rheumatic Diseases 2000 Jul;59(7):539-43.
21. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, Chung SH, Kim CG, Choe JY, Lee SW, Chung WT, Song GG. The prevalence of metabolic syndrome in patients with gout: a multicenter study. Journal of Korean Medical Science 2005 Dec;20(5):1029-33.
22. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleveland Clinic Journal of Medicine 2008 Jul;75(Suppl 5):S13-6.
23. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension (Dallas, Tex.: 1979) 2003 Jun;41(6):1183-90.
24. Ouppatham S, Bancha S, Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population. Journal of Postgraduate Medicine 2008 Oct-Dec;54(4):259-62.
25. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension (Dallas, Tex.: 1979) 2001 Nov;38(5):1101-6.
26. Feig DI, Kang D, Johnson RJ. Uric acid and cardiovascular risk. The New England Journal of Medicine 2008 Oct;359(17):1811-21.
27. Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology and clinical implications. Arthritis Research & Therapy 2008;10(3):207-16.
28. Воробьев П.А., Цурко В.В., Елисеева М.Е. Подагра в гериатрической практике. Методические рекомендации. Часть I. Клиническая геронтология 2016;22(3-4):3-9.
29. Janssens HJ, van de Lisdonk EH, Bor H, van den Hoogen HJ, Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Family Practice 2003 Aug;20(4):413-6.
30. Bhansing KJ, van Bon L, Janssen M, Radstake TR. Gout: a clinical syndrome illustrated and discussed. The Netherlands Journal of Medicine 2010 Sep;68(9):352-9.
31. Janssens HJ, van de Lisdonk EH, Janssen M, van den Hoogen HJ, Verbeek AL. Gout, not induced by diuretics? A case-control study from primary care. Annals of the Rheumatic Diseases 2006 Aug;65(8):1080-3.
32. Akkineni R, Tapp S, Tosteson ANA, Lee A, Miller KL, Choi HK, Zhu Y, Albert DA. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. The Journal of Rheumatology 2014 Apr;41(4):739-48.
33. Widecka K, Szymański FM, Filipiak KJ, Imiela J, Wożakowska-Kapłon B, Kucharz EJ, Mamcarz A, Manitius J, Tykarski A. Hyperuricemia and its treatment in patients with a high cardiovascular risk – experts opinion. Arterial Hypertension 2017;21(1):10-7.
34. Цурко В.В., Громова М.А., Елисеева М.Е. Уратснижающая терапия подагры, акцент на фебуксостат (по материалам рекомендаций Европейской антиревматической лиги). Трудный пациент 2017;15(3):24-6.
35. Цурко В.В., Громова М.А. Рационально-обоснованный подход к лечению подагры с учетом дебюта, течения и сочетанной патологии по материалам рекомендации Европейской антиревматической лиги (EULAR, 2016) Терапевтический архив 2017;89(12-2):233-7.
36. Seth R, Kydd A, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. The Cochrane Database of Systematic Reviews 2014 Oct;(10):CD006077.
37. Reinders MK, Haagsma C, Jansen TL, an Roon EN, Delsing J, van de Laar MA, Brouwers JR. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Annals of the Rheumatic Diseases 2009 Jun;68(6):892-7.
38. Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. The Cochrane Database of Systematic Reviews 2014 Nov;(11):CD010457.
39. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis and Rheumatism 2005 Mar;52(3):916-23.
40. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis and Rheumatism 2008 Nov;59(11):1540-8.
41. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research & Therapy 2010;12(2):R63.
42. Abeles AM. Febuxostat hypersensitivity. The Journal of Rheumatology 2012 Mar;39(3):659.
43. Bardin T, Chalès G, Pascart T, Flipo RM, Korng Ea H, Roujeau JC, Delayen A, Clerson P. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine 2016 May;83(3):314-7.
44. Hira D, Chisaki Y, Noda S, Araki H, Uzu T, Maegawa H, Yano Y, Morita SY, Terada T. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology 2015;96(1-2):90-8.
45. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. The New England Journal of Medicine 2005 Dec;353(23):2450-61.
46. Цурко В.В., Громова М.А. Общие принципы и основные рекомендации по ведению и лечению пациентов с подагрой по материалам обновленных европейских рекомендаций. Consilium Medicum 2017;19(12):20-4.

References

1. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. International Journal of Cardiology 2016 Jun;213:8-14.
2. Gaffo AL, Lawrence EN, Saag KG. Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Research & Therapy 2009;11(4):240-9.
3. Hari Kumar KVS, Marwaha V. Chronic tophaceous gout. International Journal of Medical and Health Sciences 2012;1(1):31-2.
4. Rheumatology. National guidance. Nasonov EL, Nasonova VA, editors. Moscow: Geotar-Media; 2008. 720 p. (In Russian).
5. Prevalence of hyperuricemia among Russian patients: according to EGIS statistics collected. Available from: http://www.egis.ru/news/232-kompaniya-egis-sobrala-statistiku-o-rasprostranennosti-giperurikemii-v-sochetanii-s-arterialnoj-gipertenziej-i-soputstvuyushchimi-zabolevaniyami-sredi-rossijskikh-patsientov Accessed 2019 Apr 24. (In Russian).
6. Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, Woolf A, March L. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases 2014 Aug;73(8):1470-6.
7. Roddy E, Choi HK. Epidemiology of gout. Rheumatic Diseases Clinic of North America 2014 May;40(2):155-75.
8. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, Burnier M. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 2004 Mar;4:9.
9. Qiu L, Cheng XQ, Wu J, Liu JT, Xu T, Ding HT, Liu YH, Ge ZM, Wang YJ, Han HJ, Liu J, Zhu GJ. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health 2013 Jul;13:664.
10. Liu S C, Xia L, Zhang J, Lu XH, Hu DK, Zhang HT, Li HJ. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS One 2015 Jul;10(7):e0134088.
11. Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Annals of the Rheumatic Diseases 2015 Apr;74(4):642-7.
12. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007 Aug;116(8):894-900.
13. Norvik JV, Storhaug HM, Ytrehus K, Jenssen TG, Zykova SN, Eriksen BO, Solbu MD. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: the Tromsø study. BMC Cardiovascular Disorders 2016;16:85-98.
14. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M, Weiss ST, Litonjua AA. Uric acid and the development of hypertension: the normative aging study. Hypertension 2006 Dec;48(6):1031-6.
15. Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. Journal of Hypertension 2007 Aug;25(8):1583-9.
16. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the third National Health and Nutrition Examination Survey. Arthritis and Rheumatism 2007 Feb;57(1):109-15.
17. Puig JG, Martínez MA. Hyperurecemia, gout and the metabolic syndrome. Current Opinion in Rheumatology 2008 Mar;20(2):187-91.
18. Borona E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998 Oct;47(10):1643-9.
19. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 Dec;288(21):2709-16.
20. Dessein P, Shipton E, Stanwix A, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Annals of the Rheumatic Diseases 2000 Jul;59(7):539-43.
21. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, Chung SH, Kim CG, Choe JY, Lee SW, Chung WT, Song GG. The prevalence of metabolic syndrome in patients with gout: a multicenter study. Journal of Korean Medical Science 2005 Dec;20(5):1029-33.
22. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleveland Clinic Journal of Medicine 2008 Jul;75(Suppl 5):S13-6.
23. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension (Dallas, Tex.: 1979) 2003 Jun;41(6):1183-90.
24. Ouppatham S, Bancha S, Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population. Journal of Postgraduate Medicine 2008 Oct-Dec;54(4):259-62.
25. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension (Dallas, Tex.: 1979) 2001 Nov;38(5):1101-6.
26. Feig DI, Kang D, Johnson RJ. Uric acid and cardiovascular risk. The New England Journal of Medicine 2008 Oct;359(17):1811-21.
27. Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology and clinical implications. Arthritis Research & Therapy 2008;10(3):207-16.
28. Vorobyev PA, Tsurko VV, Eliseyeva ME. Gout in geriatric practice. Guidelines. Part 1. Clinical Gerontology 2016;22(3-4):3-9 (In Russian).
29. Janssens HJ, van de Lisdonk EH, Bor H, van den Hoogen HJ, Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Family Practice 2003 Aug;20(4):413-6.
30. Bhansing KJ, van Bon L, Janssen M, Radstake TR. Gout: a clinical syndrome illustrated and discussed. The Netherlands Journal of Medicine 2010 Sep;68(9):352-9.
31. Janssens HJ, van de Lisdonk EH, Janssen M, van den Hoogen HJ, Verbeek AL. Gout, not induced by diuretics? A case-control study from primary care. Annals of the Rheumatic Diseases 2006 Aug;65(8):1080-3.
32. Akkineni R, Tapp S, Tosteson ANA, Lee A, Miller KL, Choi HK, Zhu Y, Albert DA. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. The Journal of Rheumatology 2014 Apr;41(4):739-48.
33. Widecka K, Szymański FM, Filipiak KJ, Imiela J, Wożakowska-Kapłon B, Kucharz EJ, Mamcarz A, Manitius J, Tykarski A. Hyperuricemia and its treatment in patients with a high cardiovascular risk – experts opinion. Arterial Hypertension 2017;21(1):10-7.
34. Tsurko VV, Gromova MA, Eliseyeva ME. Urate-lowering gout therapy, focus on Febuxostat: based on materials recommended by the European League Against Rheumatism (EULAR). Difficult Patient 2017;15(3):24-6 (In Russian).
35. Tsurko VV, Gromova MA. Rational and reasonable approach to gout treatment with regard to its debut, course and combined pathology based on the European League Against Rheumatism (EULAR, 2016) recommendations. Therapeutic Arkhive 2017;89(12-2):233-7 (In Russian).
36. Seth R, Kydd A, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. The Cochrane Database of Systematic Reviews 2014 Oct;(10):CD006077.
37. Reinders MK, Haagsma C, Jansen TL, an Roon EN, Delsing J, van de Laar MA, Brouwers JR. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Annals of the Rheumatic Diseases 2009 Jun;68(6):892-7.
38. Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. The Cochrane Database of Systematic Reviews 2014 Nov;(11):CD010457.
39. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis and Rheumatism 2005 Mar;52(3):916-23.
40. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis and Rheumatism 2008 Nov;59(11):1540-8.
41. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research & Therapy 2010;12(2):R63.
42. Abeles AM. Febuxostat hypersensitivity. The Journal of Rheumatology 2012 Mar;39(3):659.
43. Bardin T, Chalès G, Pascart T, Flipo RM, Korng Ea H, Roujeau JC, Delayen A, Clerson P. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine 2016 May;83(3):314-7.
44. Hira D, Chisaki Y, Noda S, Araki H, Uzu T, Maegawa H, Yano Y, Morita SY, Terada T. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology 2015;96(1-2):90-8.
45. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. The New England Journal of Medicine 2005 Dec;353(23):2450-61.
46. Tsurko VV, Gromova MA. General principles and basic recommendations for the management and treatment of patients with gout based on the updated European recommendations. Consilium Medicum 2017;19(12):20-4 (In Russian).
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]